Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability) (Stock Code: 0460)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 24 MAY 2022 AND DIVIDEND PAYMENT

At the annual general meeting (the "**AGM**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**") held on 24 May 2022, all the proposed resolutions as set out in the notice of the AGM dated 20 April 2022 were taken by way of poll.

As at the date of the AGM, the total number of issued shares of the Company was 9,329,999,206 shares, which was the total number of shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There were no restrictions on any shareholders of the Company ("**Shareholders**") casting votes on any of the proposed resolutions at the AGM. There were no shares entitling the holder to attend and abstain from voting in favour of the proposed resolutions at the AGM under Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). No Shareholder was required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM. No party has stated its intention in the circular of the Company dated 20 April 2022 that it would vote against any proposed resolution or that it would abstain from voting at the AGM.

The Hong Kong branch share registrar of the Company, Tricor Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All the resolutions were approved by the Shareholders. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

		ORDINARY RESOLUTIONS	No. of Votes (%)		
ORDINARY RESOLUTIONS			For	Against	
1.	stater direc of th	eceive and adopt the audited consolidated financial ments of the Company and the reports of the tors of the Company (the " Directors ") and auditors e Company (the " Auditors ") for the year ended 31 ember 2021.	5,343,655,474 (99.88%)	6,280,286 (0.12%)	
2.	To approve the declaration and payment of a final cash dividend for the year ended 31 December 2021.		5,349,935,760 (100.00%)	0 (0.00%)	
3.	To approve the declaration and payment of a special cash dividend for the year ended 31 December 2021.		5,349,935,760 (100.00%)	0 (0.00%)	
4.	(a)	To re-elect the following retiring Directors:			
		(i) Dr. Che Fengsheng as an executive Director	5,332,832,537 (99.68%)	17,103,223 (0.32%)	
		(ii) Dr. Guo Weicheng as an executive Director	5,342,420,533 (99.86%)	7,312,227 (0.14%)	
		(iii) Dr. Zhu Xun as an independent non-executive Director	5,345,187,097 (99.91%)	4,748,663 (0.09%)	
		(iv) Mr. Tsang Wah Kwong as an independent non- executive Director	5,321,941,636 (99.48%)	27,791,124 (0.52%)	
	(b)	To authorize the board of Directors (the " Board ") to fix the remuneration of the Directors	5,349,775,659 (99.99%)	160,101 (0.01%)	
5.	To re-appoint Ernst & Young as Auditors and authorize the Board to fix their remuneration.		5,349,732,760 (100.00%)	0 (0.00%)	

		ODDINA DV DESOL UTIONS	No. of Votes (%)	
ORDINARY RESOLUTIONS			For	Against
6.	(A)	To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20 per cent of the number of issued shares of the Company.	5,150,709,639 (96.28%)	199,226,121 (3.72%)
	(B)	To give a general mandate to the Directors to repurchase shares not exceeding 10 per cent of the number of issued shares of the Company.	5,349,935,760 (100.00%)	0 (0.00%)
	(C)	To extend the authority given to the Directors pursuant to ordinary resolution no. $6(A)$ to issue shares by adding to the number of issued shares of the Company the number of shares repurchased under ordinary resolution no. $6(B)$.	5,151,113,740 (96.28%)	198,822,020 (3.72%)

As more than 50% of votes were casted in favour of the resolutions numbered 1 to 6, all the above resolutions were duly passed as ordinary resolutions.

Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Mr. Choi Yiau Chong, Ms. Chen Yanling, Mr. Tsang Wah Kwong and Dr. Zhu Xun attended the AGM. Mr. Patrick Sun was unable to attend the AGM due to personal engagements.

FURTHER INFORMATION ON THE PAYMENT OF THE FINAL CASH DIVIDEND AND THE SPECIAL CASH DIVIDEND

The proposed final cash dividend of RMB1.3 cents per share and the proposed special cash dividend of RMB9.5 cents per share in respect of the year ended 31 December 2021 have been approved by the Shareholders at the AGM. The final cash dividend and the special cash dividend payable to Shareholders shall be converted to and paid in Hong Kong dollars. The exchange rate adopted for conversion was based on the exchange rate of RMB1 to HKD1.2302 as of 29 March 2022. Accordingly, the amount of the final cash dividend and the special cash dividend payable in Hong Kong dollars will be HK1.6 cents per share and HK11.7 cents per share, respectively.

By order of the Board Sihuan Pharmaceutical Holdings Group Ltd. Dr. Che Fengsheng Chairman and Executive Director

China, 24 May 2022

As at the date of this announcement, the executive Directors are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive Directors are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.